renovorx is a medical device company headquartered in silicon valley, california. we are developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. the ability to deliver these materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of our technology. we have received fda clearance for the renovocath™ rc120 and are now introducing our innovative technology to the clinical market. renovorx is a highly motivated team with broad experience and an exciting vision for the future of targeted delivery. we are backed by a broad medical advisory board and a strong board of directors. please contact us at info@renovorx.com to learn more.
Company profile
Ticker
RNXT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
271448452
RNXT stock data
Latest filings (excl ownership)
8-K
Other Events
18 Apr 24
8-K
Other Events
16 Apr 24
8-K
Unregistered Sales of Equity Securities
15 Apr 24
S-8
Registration of securities for employees
12 Apr 24
8-K
RenovoRx Announces $11.1 Million At Market Private Placement
9 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Feb 24
8-K
Departure of Directors or Certain Officers
9 Feb 24
D
Exempt offering of security
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.23 mm | 3.23 mm | 3.23 mm | 3.23 mm | 3.23 mm | 3.23 mm |
Cash burn (monthly) | 909.33 k | (no burn) | 994.33 k | 982.42 k | 909.33 k | 823.83 k |
Cash used (since last report) | 6.08 mm | n/a | 6.64 mm | 6.56 mm | 6.08 mm | 5.50 mm |
Cash remaining | -2.85 mm | n/a | -3.42 mm | -3.34 mm | -2.85 mm | -2.28 mm |
Runway (months of cash) | -3.1 | n/a | -3.4 | -3.4 | -3.1 | -2.8 |
Institutional ownership, Q2 2023
9.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 1 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 558.26 mm |
Total shares | 1.52 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kamran Najmabadi | 731.25 k | $3.54 mm |
BSX Boston Scientific | 543.97 k | $2.63 mm |
Cohen Lawrence B | 97.17 k | $219.59 mm |
Vanguard | 55.48 k | $125.39 mm |
Geode Capital Management | 42.10 k | $95.15 mm |
Level Four Advisory Services | 15.00 k | $33.90 mm |
Affinity Capital Advisors | 13.28 k | $30.01 mm |
Susquehanna International | 12.36 k | $27.94 mm |
Tower Research Capital | 8.72 k | $19.71 mm |
MS Morgan Stanley | 176.00 | $398.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Leesa Gentry | Options Common Stock | Grant | Acquire A | No | No | 1.69 | 190,000 | 321.10 k | 190,000 |
9 Feb 24 | Ron Kocak | Options Common Stock | Grant | Acquire A | No | No | 1.59 | 15,000 | 23.85 k | 15,000 |
26 Jan 24 | Kirsten Angela Macfarlane | Common Stock | Buy | Acquire P | No | No | 0 | 40,983 | 0.00 | 40,983 |
26 Jan 24 | Kirsten Angela Macfarlane | Warrant Shares Common Stock | Buy | Acquire P | No | No | 1.22 | 40,983 | 50.00 k | 40,983 |
News
RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
8 Apr 24
Alliance Global Partners Initiates Coverage On RenovoRx with Buy Rating, Announces Price Target of $4
2 Feb 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
31 Jan 24
Press releases
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
16 Apr 24
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology
16 Apr 24
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology
15 Apr 24
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
15 Apr 24
RenovoRx Announces $11.1 Million at Market Private Placement
8 Apr 24